Gene eRandomized Controlled Trial of the Gastrin Receptor Antagonist Netazepide in Patients with Barrett’s Esophagus

A randomized, double-blind, placebo-controlled trial of netazepide (YF476) in patients with BE without dysplasia was performed. Gene expression before and after treatment with netazepide and with a placebo was measured with RNASeq Gene expression of Barrett's esophogus of patients treated with netazapeptde 25 mg or placebo once daily for 12 weeks before and after treatment. aa.pla.t1 placebo arm, before treatment with placebo, n=9. ab.pla.t2 placebo arm, after treatment with placebo, n=9. ba.trt.t1 treatment arm, before treatment with netazapeptide, n=10. bb.trt.t12treatment arm, after treatment with treatment with netazapeptide, n=10.